INAB-CERTH will perform during the study conduct the following assessments that are required by the study protocol and detailed in Exhibit A: 1. NGS Immunoprofiling experiments 2. WES experiments 3. RNA seq experiments 4. Peptide pools. Functional T cell assays.
Ο στόχος του έργου CLLon ήταν η κατανόηση των διαδικασιών που σχετίζονται με το ρόλο της ανοσοσφαιρίνης του Β κυτταρικού υποδοχέα (B cell receptor immunoglobulin, BcR IG) που συμβαίνουν κατά τη διάρκεια της φυσικής ιστορίας της ΧΛΛ και συμβάλλουν στην οντογένεση και την εξέλιξη της νόσου μέσω της μελέτης του κλωνοτυπικού BcR IG σε ανοσογενετικό και λειτουργικό επίπεδο. Για την εξαγωγή ισχυρών συμπερασμάτων, η ομάδα μελέτης περιλάμβανε άτομα με ΜΒΛ και των δύο υποτύπων: (i) ΜΒΛ χαμηλού αριθμού κυττάρων (low-count MBL, LC-MBL) και (ii) MBL υψηλού αριθμού κυττάρων (high-count MBL, HC-MBL), καθώς και ασθενείς με ΧΛΛ με διακριτή κλινικά πορεία της νόσου, η οποία κυμαινόταν από εξαιρετικά σταθερή (ασυμπτωματικοί ασθενείς για τουλάχιστον 10 χρόνια) έως ταχέως εξελισσόμενη. Πραγματοποιήθηκε πολυπαραμετρικός χαρακτηρισμός των ιδιοτήτων του Β κυτταρικού υποδοχέα στη ΜΒΛ και τη ΧΛΛ σε διαφορετικά επίπεδα: (i) ανάλυση δεδομένων αλληλουχιών βαριάς και ελαφριάς αλυσίδας IG, (ii) προφίλ αντιδραστικότητας του Β κυτταρικού υποδοχέα και (iii) ικανότητα σηματοδότησης μέσω του Β κυτταρικού υποδοχέα (κλασική και αυτόνομη).
The Joint Action on integrating prevention, testing and link to care strategies across HIV, Viral Hepatitis, TB & STIs in Europe” (INTEGRATE) has the overall objective to improve the understanding and implement integrated activities related to early diagnosis of HIV, viral hepatitis, TB and STIs and linkage to prevention and care in partner countries. A number of tools have been developed to reduce transmission, optimize early diagnosis and linkage to care for one or more of these four diseases. INTEGRATE will map relevant existing tools for cross-linking. A peer-review process will identify which of these tools are complimentary or redundant for other disease(s), and which could be adapted or require further innovation. HIV, viral hepatitis, TB and STIs are cross-borders public health threats of concern to Europe that affect vulnerable populations disproportionately and require personalised interventions. As multiple dimensional approaches are required to reduce the public health burden, the most optimal profile of approaches that provide additive effects (and that are reasonably cost-effective) should be identified and implemented broadly. INTEGRATE provides a platform to disseminate and exchange best practice among Member States and facilitate discussions on innovations and emerging issues within the four diseases. In this respect, INTEGRATE is a shared European effort that extends beyond the partners and can create important synergies across European stakeholders, projects and initiatives.
Europe is paying a heavy price for chronic diseases (CD): it has been estimated that CD cost EU economies 115 billion € or 0.8% of GDP annually; and this figure does not include the additional loss in terms of lower employment rates and productivity of people living with chronic health problems. However, the aspiration is a health-promoting Europe, free of preventable CD, premature death and avoidable disability could be possible. Initiatives on CD should build on four cornerstones: health promotion and primary prevention as a way to reduce the burden of CD; patient empowerment; tackling functional decline and quality of life as the main consequences of CD, and making health systems sustainable and responsive to the aging of our populations associated with the epidemiological transition (an increase in incidence of CD and extended life expectancy) whose consequence is an increasing prevalence of CD. In this Joint Action, CHRODIS-PLUS, our goal is to support Member States through cross-national initiatives identified in JA-CHRODIS to reduce the burden of CD, while assuring health systems sustainability and responsiveness. CHRODIS-PLUS aims to promote the implementation of policies and practices with demonstrated success in each of the four cornerstones mentioned, in closely monitored implementation experiences that can be validated before scaling them up. Practices to be implemented will be based on the collection of policies, strategies and interventions that started in JA-CHRODIS and in its outputs such as the Integrated Multimorbidity Care Model or the recommendations for Diabetes Quality criteria or national plans.
ΜyPal aims to foster early palliative care for cancer patients by leveraging patient reported outcome (PRO) systems through their adaptation to the personal needs of the cancer patient and his/her caregiver(s). Through this intervention, MyPal aspires to empower cancer patients (and their family members) in capturing more accurately their conditions, communicate them with a seamless and effective way to their healthcare providers and, ultimately, foster the time for action through the rapid identification of important deviations in the patient’s state and QoL. Providing this information in a timely and comprehensive manner throughout the disease course will reinforce the potential for applying a patient-centred and integrated palliative care approach for cancer with the participation of all relevant healthcare providers (i.e. oncologists, specialized physicians, psychologists, nurses), which is necessary to cope with the specific disease. In order to accomplish its mission, MyPal will exploit technological advances on digital health to support patients, family members and healthcare providers in gaining value through this systematic and comprehensive PRO-based intervention. Overall, the foreseen advancement through MyPal reflects a paradigm shift from passive patient reporting based on conventional PRO approaches to active patient engagement and a closed-loop approach (bridging the gap between patient reporting and effective actions by healthcare providers to meet the varying patient needs) for coping with palliative care challenges in cancer.
Το επιστημονικό αντικείμενο του έργου συνίσταται στη σύμφωνη με τους κανόνες της επιστήμης γονιδιωματική επιτήρηση του ιού SARS-CoV-2, σύμφωνα με τις οδηγίες της αρμόδιας Επιτροπής καταπολέμησης Λοιμογόνων Παραγόντων του Υπουργείου Υγείας και τις κατευθυντήριες οδηγίες του Ευρωπαϊκού Κέντρου Πρόληψης και Ελέγχου Νόσων (ECDC). Ο σκοπός της παρούσας προγραμματικής σύμβασης έγκειται στη συνεργασία των συμβαλλομένων μερών, η οποία αποσκοπεί στη διασφάλιση της επίτευξης του κοινού τους στόχου για την αντιμετώπιση του ιού SARS-CoV-2 και για την κάλυψη των αναγκών εργαστηριακής επιτήρησης σε επίπεδο γονιδιώματος του ιού SARS-CoV-2, μέσω της αλληλούχησης.
Το επιστημονικό αντικείμενο του έργου συνίσταται στη σύμφωνη με τους κανόνες της επιστήμης γονιδιωματική επιτήρηση του ιού SARS-CoV-2, σύμφωνα με τις οδηγίες της αρμόδιας Επιτροπής καταπολέμησης Λοιμογόνων Παραγόντων του Υπουργείου Υγείας και τις κατευθυντήριες οδηγίες του Ευρωπαϊκού Κέντρου Πρόληψης και Ελέγχου Νόσων (ECDC). Ο σκοπός της παρούσας προγραμματικής σύμβασης έγκειται στη συνεργασία των συμβαλλομένων μερών, η οποία αποσκοπεί στη διασφάλιση της επίτευξης του κοινού τους στόχου για την αντιμετώπιση του ιού SARS-CoV-2 και για την κάλυψη των αναγκών εργαστηριακής επιτήρησης σε επίπεδο γονιδιώματος του ιού SARS-CoV-2, μέσω της αλληλούχησης.
Το επιστημονικό αντικείμενο του έργου συνίσταται στη σύμφωνη με τους κανόνες της επιστήμης διενέργεια τεστ δοκιμασίας για SARS-CoV-2, και η γονιδιωματική επιτήρηση του ιού SARS-CoV-2και εξέταση μοριακών δειγμάτων (PCR), σύμφωνα με τις οδηγίες της αρμόδιας Επιτροπής καταπολέμησης Λοιμογόνων Παραγόντων του Υπουργείου Υγείας και τις κατευθυντήριες οδηγίες του Ευρωπαϊκού Κέντρου Πρόληψης και Ελέγχου Νόσων (ECDC). Ο σκοπός της παρούσας προγραμματικής σύμβασης έγκειται στη συνεργασία των συμβαλλομένων μερών, η οποία αποσκοπεί στη διασφάλιση της επίτευξης του κοινού τους στόχου για την κάλυψη των διαγνωστικών αναγκών μέσω της άμεσης εργαστηριακής διερεύνησης λαμβάνοντας υπόψη τις αυξημένες απαιτήσεις για τη διενέργεια εργαστηριακών εξετάσεων για την αντιμετώπιση του ιού SARS-CoV-2 και για την κάλυψη των αναγκών εργαστηριακής επιτήρησης σε επίπεδο γονιδιώματος του ιού SARS-CoV-2, μέσω της αλληλούχισης όλου του γονιδιώματος του ιού, λαμβάνοντας υπόψη τις αυξημένες απαιτήσεις για τη διενέργεια γονιδιωματικού ελέγχου για την αντιμετώπιση του ιού SARS-CoV-2 σύμφωνα με τις οδηγίες της αρμόδιας Επιτροπής καταπολέμησης Λοιμογόνων Παραγόντων του Υπουργείου Υγείας και του Ευρωπαϊκού Κέντρου Πρόληψης και Ελέγχου Νόσων(ECDC).
Subject to the Consortium Agreement, Beneficiaries shall participate in the provision and/or facilitate the access to anonymized patient’s datasets. The European Research Initiative on CLL e.v. (ERIC) acts as Research Coordinator in the data collection and the implementation of a Bench-to-bedside research project to study to determine the incidence and prevalence of other malignancies both preceding or following CLL diagnosis and their impact on the disease course and overall survival (OS). The European Research Initiative on CLL e.v. (ERIC) has facilitated the structure of the collected data, to be provided to HARMONY, and is entitled to act and sign this agreement on behalf of the Acceding Data Providers listed in Annex 3, who own the data generated from their quality assistance and healthcare activities and studies in the field of hematology. The Parties acknowledge the sensitive nature of the health data at stake and aim at protecting the interests, fundamental rights and freedoms of the patient’s by a combination of technical and organizational measures ensuring an effective anonymization of the Contributed Data.
The purpose of this AMEF is to establish the overarching framework for initiating collaboration between the Parties; to identify and describe data of interest to pursue the general goals of HARMONY. This AMEF only describes the data held or controlled by the Associated Member in a general way. Any transfer and/or use of such data by the HARMONY beneficiaries requires a separate Associated Member Data Sharing Agreement (‘AMDS’).
Οι νέες επιστημονικές εξελίξεις στον χώρο των Β-κακοηθειών έχουν αυξήσει εντυπωσιακά τη γνώση για τις νόσους αυτές καθώς και την αποτελεσματικότητα στην αντιμετώπισή τους με νέες θεραπείες. Η ραγδαία αυτή πρόοδος ιδιαίτερα στον τομέα της θεραπευτικής καθιστά αναγκαία τη βαθύτερη εκπαίδευση των επαγγελματιών υγείας για την πληρέστερη κατανόηση της δράσης των φαρμακευτικών σκευασμάτων αλλά και των πιθανών ανεπιθύμητων ενεργειών τους. Το Ινστιτούτο κατέχει τεκμηριωμένη γνώση για όλα τα παραπάνω επιστημονικά ζητήματα, καθώς διεξάγει πρωτοποριακή και διεθνώς αναγνωρισμένη σχετική έρευνα και επίσης έχει σημαντική εμπειρία στη βέλτιστη εκπαίδευση στο συγκεκριμένο επιστημονικό πεδίο. Σκοπός είναι η δημιουργία εκπαιδευτικού υλικού που αφορά στο βέλτιστο χειρισμό των ανεπιθύμητων αντιδράσεων που σχετίζονται με τη χορήγηση της λεναλιδομίδης και της πομαλιδομίδης κατά τη τη θεραπευτική αντιμετώπιση του Πολλαπλού Μυελώματος , αποσκοπώντας στην πληρέστερη μετάδοση της γνώσης προς την ευρύτερη επιστημονική κοινότητα. Αντικείμενο της παρούσας Σύμβασης είναι η δημιουργία, άλλως η συγγραφή και διαμόρφωση ενός Πρακτικού Οδηγού – Εγχειριδίου που θα απευθύνεται σε Αιματολόγους Ιατρούς και Επαγγελματίες Υγείας συναφών ειδικοτήτων, με περιεχόμενο που περιγράφεται στο Παράρτημα Ι το οποίο αποτελεί ενιαίο και αναπόσπαστο τμήμα της παρούσης.
Εκπόνηση καταγραφής δεδομένων που αφορά α) στην εκτίμηση των αναγκών της φροντίδας όπως τις αντιλαμβάνονται και τις εκφράζουν τόσο τα οροθετικά άτομα που βρίσκονται σε φροντίδα στις μονάδες λοιμώξεων στην ελληνική επικράτεια όσο και οι ιατροί που ασχολούνται με την HIV λοίμωξη και β) στην εκτίμηση επιδημιολογικών και κλινικοεργαστηριακών παραμέτρων των ασθενών σε συνδυασμό με επιστημονικά εργαλεία (τύπου ερωτηματολογίων) αξιολόγησης της ποιότητας ζωής που σχετίζεται με την υγεία, των στάσεων και αντιλήψεων για τη νόσο και τη θεραπεία της καθώς και τη συμμόρφωση στη χρόνια θεραπεία της HIV λοίμωξης.
CERTH will coordinate together with other partners (Univ Paris-D, Univ Paris-MC) a WorkPackage on Bioinformatic approaches for antigen receptor gene repertoire analysis in lymphoid malignancies. For this purpose an immunoinformatics pipeline for NGS-based IG/TR gene repertoire (meta) analysis needs to be created to address generic challenges. Additionally, statistics and algorithms for IG somatic hypermutation analysis and interpretation in lymphoid malignancies need to be developed. This platform shall also impact on the broader EuroClonality-NGS activities."
The goal of the 2016 Global Patient Survey was to gather information that will assist LC and its members begin to understand the patient experience, through examination of the following issues: 1) At the start of their journey, to what degree have patients been made aware of and had an understanding of their diagnosis, subtype, treatment options and adverse-effect management? Of those who did not have an understanding, who are they?, 2) How are patients being affected by treatment? What specific physical and psychosocial conditions, and medical issues have patients been living with, and at what stage of their experience? Are relapsed patients more susceptible to issues?, 3) Who is most affected by lifestyle and independence issues? Does discrimination tend to be an issue?, 4) Have healthcare professionals been effective in providing patients with information and support? Which patients are not reaching out for help?, 5) What role have various support services and healthcare professionals played during the patient journey? What have been the patient’s primary sources for information and support? Moving forward, in which types of support services would patients be most interested?, 6) Specifically, who is experiencing barriers to receiving adequate lymphoma treatment?
This project builds on existing close collaboration between the network of collaborating hematology centers in Greece. It also represents the extension of our relevant ongoing activities focused on the creation of a standardized clinic-biological data registration system for patients attended at the Hematology Department and HCT Unit of the G. Papanicolaou Hospital in Thessaloniki, Greece, where the proponent of the present proposal holds the position of Head of the Laboratory of Molecular Diagnostics and Scientific Advisor for Basic and Translational Research. As mentioned in the preceding paragraph, results from the pilot phase of this initiative have already been published/presented, offering proof of concept for the feasibility and scope of the proposal. The system will essentially be based on a systematic cataloguing and clear understanding of the data types to be collected, their categories, their relationships, and their properties. The first milestone will be performed through face-to-face meetings between (bio)informatics and hospital staff as well as a constant exchange of a purpose-built electronic spreadsheet, which contains the data types and structures, i.e. in different columns and sheets.
COSMIC develops and integrate experimental and computational approaches and establish a unique crossfertilization between oncology and auto-immunity. In addition to transferable skills, the training program focuses on establishing a double expertise in laboratory and computational to address clinical questions. It involves a wide-range of stakeholders: (pre)clinical departments, companies, patient groups, students, and the general public. COSMIC will establish a link with the leading European EASyM and ISBE initiatives, and aims to harmonize systems medicine training throughout Europe by connecting to other EU (Marie Curie systems medicine) training initiatives. Impact: COSMIC (i) significantly improves ESR career perspectives (ii) leads to new public-private collaborations increasing competitiveness for companies; (iii) contributes to future oncology and immunology medical care; (iv) contributes to the EU systems medicine best practices.
The aim of this project is to investigate relevant pathogenetic mechanisms of Chronic lymphocytic leukemia (CLL) by dissecting the interactions occurring between the B Cell Receptor and yet unknown antigens. This will provide the basis for designing innovative and selective therapeutic strategies. CLL is the most frequent leukemia among adults in the western world, due to the accumulation of mature neoplastic B lymphocytes. CLL is an incurable disease, despite the use of intensive and costly immuno-chemotherapeutic treatments, leading to great distress for patients and their families as well as huge social costs for both public and private health care systems. A way to overcome resistance to therapy will derive from a better understanding of the molecular mechanisms of the disease that may lead to the identification of novel molecular targets for therapy. CLL is considered as a typical multifactorial disease where genetic and (micro)environmental elements concur to its pathogenesis: genetic events play a relevant role in initiating CLL but it is evident that stimuli originating from the microenvironment are responsible for maintaining and propagating the disease. Therefore, CLL may be seen as a model to elucidate the pathogenesis of cancer in general as it may reveal common oncogenic pathways acting in other neoplastic diseases.
Chronic lymphocytic leukemia faces high-challenging and timely problems related to the classification and efficient prognosis of patients at the time of diagnosis and the attempt to personalize the treatment. CLLassify addresses these issues in a pioneering fashion within a multidisciplinary collaboration, proposing an improved classification of the patients, based on innovative statistical techniques as well as the novel aspect of personalized prediction of the need for treatment at a specific time point for the individual patient. The statistical background of the applicant, together with the expertise of his supervisor in CLL, guarantee the successful implementation of this project. This will result both in significant health advances and societal benefits for the European society at large raising the project at the level of a European priority, and to significant improvement of the applicant’s career prospects within Europe.
Ageing population is steeply increasing worldwide. A consequence of age related decline is the clinical condition of frailty. Frailty is a biological syndrome of decreased reserve and resistance to stressors, resulting from cumulative declines across multiple physiologic systems and causing vulnerability to adverse outcomes. Susceptibility to stressors is influenced by biological, behavioral, environmental, and social risk factors, with the main consequence being an increased risk for multiple adverse health outcomes, including disability, morbidity, falls, hospitalization, institutionalization, and death. However, frailty is a dynamic and not an irreversible process; it seems preventable, may be delayed, or reversed. Our understanding of frailty has markedly improved over the last five years, yet there are many issues yet to be resolved. FrailSafe aims to better understand frailty and its relation to co-morbidities; to identify quantitative and qualitative measures of frailty through advanced data mining approaches on multiparametric data and use them to predict short and long-term outcome and risk of frailty; to develop real life sensing (physical, cognitive, psychological, social) and intervention (guidelines, real-time feedback, AR serious games) platform offering physiological reserve and external challenges; to provide a digital patient model of frailty sensitive to several dynamic parameters, including physiological, behavioural and contextual.
The main goal of MEDGENET consortium is to use synergies and existing expertise in EU leading institutions such as EMBL, Uppsala University and CERTH to reinforce the productivity and competitiveness of the CEITEC in the field of medical genomics and epigenomics. We propose clear strategy based on combination of unique complementary skills present in partner institutions that will transform CEITEC into a key leader in the field. ERA Chair who recently joint CEITEC already initiated the transformational change of the institute and TWINNING framework will further support sharing her international contacts with other CEITEC researchers. MEDGENET aims to create well-educated taskforce of biomedical researchers, who will notably contribute to the development of new genomics and bioinformatics tools and their application in clinical practice. Proposed project will enable to establish the best practices for performing innovative and high-quality biomedical research and to strengthen CEITEC´s competence to translate the research results into high value-added clinical applications. Stimulation of knowledge exchange, implementation of cutting edge technologies and mastery of modern genomics and bioinformatics methodologies will have a direct impact on the overall research and innovation potential of CEITEC and will increase its visibility in the international scientific community.
CGI-Clinics aims at improving personalised medicine in oncology by optimizing genomic data interpretation (after sequencing and before advising on compatible targeted therapies). Interpretation is a bottleneck for the full deployment and broad accessibility of Next Generation Sequencing (NGS) in cancer management. The project tackles the 3 main hurdles in the interpretation of cancer mutations: it is not systematic, it deals with a majority of variants of unknown significance and it fails to empower patients. The interpretation of tumor genomic data relies on the work of experts reviewing scattered databases and resources, in a timeconsuming process that may lead to suboptimal clinical decisions. CGI-clinics will systematize the interpretation process by integrating relevant public and private databases hospitals in a one-stop shop tool, with the possibility to organize virtual molecular tumor boards co-facilitated by reference hospitals. Project will have three phases: a setup (assess needs), validation and replication (30 hospitals across EU). It will enable democratization of genomic data interpretation (independent of their size, resources and profiling technology) and provide health economics validation. Relying on a systematic automatic learning platform, GCI-Clinics will increase the share of interpretable variants in tumors, and features that constitute biomarkers of drug response. CGI-Clinics will build eduCGI, an app to help them understand the information gained through interpretation of their tumors, facilitating informed discussions with clinicians and sharing their data for research.
